Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: biomachine56 who wrote (2186)	5/30/2013 8:53:04 AM
From: biomachine56	Respond to of 2344

PX-866 Update The Company's randomized Phase 2 portion of its Phase 1/2 trial of PX-866 in combination with cetuximab did not meet the primary endpoint of an improvement in overall response rate compared to cetuximab alone in patients with metastatic colorectal cancer. The secondary endpoint of an improvement in progression-free survival was also not met. The trial enrolled a total of 85 patients. The data will be submitted for presentation at a subsequent scientific meeting.